Clarivate Epidemiology's coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for…
Clarivate Epidemiology's coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for…
Clarivate Epidemiology's coverage of schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of schizophrenia for…
Abstract here
Abstract here
Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint…
The treatment landscape for COVID-19 is rapidly evolving, as such, intense research is focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected…
DRG Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany,…
Clarivate Epidemiology's coverage of myasthenia gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and…
The drug landscape for major depressive disorder (MDD) consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Agents for treating MDD span…
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…
Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant…
Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity…
The approval two CAR T-cell therapies for relapsed / refractory B-cell hematological malignancies—Novatis’ Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite…
Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s…